Coverage for PREVYMIS® (letermovir)
The Merck Access Program for PREVYMIS may be able to help answer questions about insurance coverage for patients, benefit investigations, and the prior authorization and appeals process.
The Merck Access Program for PREVYMIS may be able to help answer questions about insurance coverage for patients, benefit investigations, and the prior authorization and appeals process.
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Before prescribing PREVYMIS® (letermovir), please read the accompanying Prescribing information. The Patient information also is available.
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV)
PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT)
Before prescribing PREVYMIS® (letermovir), please read the accompanying Prescribing information. The Patient information also is available.
PREVYMIS is contraindicated in patients receiving pimozide.